Eric Lefkofsky is the co-founder and CEO of Tempus, Inc and graduate of University of Michigan Law School. His company focuses on cancer research and is in collaboration with the Nation Cancer Institute. The company is just under 4 years old, but somehow they have made several advancements in modern medicine and raised 130 million dollars in funding for cancer research.
Even though the company devotes most of its attention to cancer research, the company is responsible for a few of the newest breakthroughs in medicine.
Since the company was created in 2015, they have accomplished groundbreaking work in gene therapy and gene editing and have created biotechnologies that can be used to treat diseases that were believed to be untreatable prior to the biotechnologies creation.
In 2017, Lefkofsky and company were delighted to hear that the FDA approved their new medicine for use with patients that have a rare form of inherited vision lost.
Tempus are behind new pathogen sequencing technology that allows for rapid sequencing of pathogen genomes. These tools allow for rapid public response, should an unknown disease suddenly appear in an isolated location.
Tempus has created the worlds first smartwatch meant to monitor blood pressure.
The most impressive thing on the list of accomplishments by Tempus may be new immunotheraphy for cancer. Axicabtageneciloleucel(marketed as Yescarta), treats the patients refractory aggressive B-cell non-Hodgkin lymphoma and a drug marketed as Kymriah is for pediatric and youg adult patients with acute lymphoblastic leukemia. Both of which have recently been approved by the FDA.
When Lefkofsky isn’t leading the world in cancer research he is working with his charity, The Lefkofsky Family Foundation. He established the foundation in 2006 and has been working to expand cultural initiatives, propel medial research, and work for expanded human rights for women and girls.
Eric Lefkofsky’s Social Media: www.facebook.com/eplefkofsky/